Village Farms has 175 per cent upside, Echelon Wealth says

With its well-proven chops in growing greenhouse tomatoes and other produce, BC-based Village Farms International (Village Farms Stock Quote, Chart, News: TSX:VFF) is a good bet to succeed in the cannabis market as well says analyst Russell Stanley of Echelon Wealth Partners.

In a research update to clients on Monday, Stanley maintains his “Speculative Buy” rating and $13.00 target price for VFF.

On Monday, Village Farms announced it has entered a supply agreement as part of its joint venture with licensed cannabis producer Emerald Health Therapeutics (TSXV:EMH), under which Emerald agrees to purchase 40 per cent of the JV’s production volumes in 2018 and 2019 at a pre-determined price.

Stanley views the agreement positively, saying that it gives the joint venture sales and revenue visibility while at the same time providing flexibility to VFF to pursue sales opportunities with provincial governments and other LPs.

“While the price per gram has not yet been disclosed, our model assumes VFF realizes $4.00/gram on dried flower sales,” says the analyst. “Management believes this agreement will cover 21,000–24,000kg, based on their production estimates of 7,000–8,000kg in 2018 (versus our estimate of just under 4,000kg) and 46,000–52,000kg in 2019 (versus our estimate of just over 30,200kg).”

“We note that our estimates are very conservative relative to management’s, and given VFF’s long track record in cost-effective greenhouse production, we believe there is considerable room for upward revisions to our forecast. In fact, the supply agreement effectively locks up a buyer for 75 per cent of our F2018 production estimate, and 65 per cent of our F2019 estimate,” he says.

Stanley estimates that at 5.6x EV/C2019E EBITDA, VFF trades at the lowest multiple of its peer group of cannabis companies, representing a 41 per cent discount to the 10.0x adjusted average multiple of its closest peers and a 59 per cent discount to the 13.1x adjusted average of the broader peer group.

The analyst’s target price of $13.00 represents a projected return of 175 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: vff
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

33 mins ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

1 hour ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 hours ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

16 hours ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

1 day ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

1 day ago